ArticleCureus2025
Economic Burden and Clinical Epidemiology of Dialysis: A Cross-Sectional Analysis of Chronic Kidney Disease Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of probiotic and synbiotic administration on the nutritional status of hemodialysis patients: a randomized-controlled trial.International urology and nephrology · 2026Trial
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney disease (CKD) represents a rising global health burden, with millions requiring dialysis as a form of kidney replacement therapy. In low- and middle-income countries such as Pakistan, dialysis care is partially subsidised, but patients often face substantial out-of-pocket (OOP) costs, creating financial strain.
methodsThis descriptive, cross-sectional study was conducted at a dialysis unit of a secondary care hospital in Pakistan. All patients on maintenance hemodialysis were invited to participate; the response rate was 80.8%. Data were collected through structured questionnaires and review of medical records. Demographic, clinical, and economic variables were captured, including comorbidities, dialysis duration and frequency, use of supportive therapies, and direct, indirect medical and non-medical costs in 2024 US dollars (USD). Statistical analysis was done using IBM SPSS Statistics version 26.0 (IBM Corp., Armonk, NY, USA).
resultsThe cohort comprised 42 patients, 66.7% of whom were male (n = 28), with a mean CKD duration of 6.8 ± 5.2 years and a median dialysis duration of 1.0 year (IQR, 0.6-2.0 years). The mean age of the cohort was 58.3 ± 13.7 years (range, 25-83 years). Most (95.2%) were on twice-weekly hemodialysis. Despite full coverage of dialysis sessions through the Sehat Sahulat Programme, all patients incurred recurrent OOP costs. The median monthly "basic bundle" (consultation, labs, medications) cost was Pakistani rupees (PKR) 22,100 (approximately USD $78.40), equivalent to a mean annual cost of PKR 316,057 ± 149,030 (USD $1,121.55 ± $528.92). Additional costs included erythropoietin (85.7%, median PKR 7,600/month), blood transfusions (42.9%, median PKR 12,000/year), hospitalisations (38.1%, median PKR 190,000/year), transport (median PKR 4,800/month), and special diet (57.1%, median PKR 10,000/month). Using cumulative burden thresholds, 28.6% of households exceeded 100% of their monthly household income for expanded costs (4.8% for basic costs).
conclusionDialysis patients in Pakistan carry a heavy dual burden of disease and economic hardship. While sessional dialysis is publicly financed, significant ancillary costs remain, often exceeding household income and driving catastrophic health spending. Policies expanding financial protection to include medications, laboratory testing, nutrition, and transport are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.